How big is the short-acting insulin market today, and what are its future growth expectations?
The short-acting insulin market size has grown strongly in recent years. It will grow from $11.00 billion in 2024 to $11.65 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to an increase in the type 1 diabetes population, a rising geriatric population, a surge in research and development funding, the prevalence of diagnosed instances, and increasing urbanization.
The short-acting insulin market size is expected to see strong growth in the next few years. It will grow to $14.47 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to an increase in initiatives taken by the government, an increase in government support, rapid innovations in production, increasing adoption of insulin therapy, and the rise of personalized medicine. Major trends in the forecast period include advancements in insulin delivery devices and technologies, innovative fast-acting insulin analogs, the development of biosimilars, a shift towards patient-centric care, and advancements in formulation.
Get Your Free Sample of The Global Short-Acting Insulin Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp
What have been the primary factors driving the short-acting insulin market’s growth?
The increasing prevalence of type 1 diabetes is expected to fuel the growth of the short-acting insulin market going forward. Type 1 diabetes is an autoimmune condition where the body destroys insulin-producing cells, requiring lifelong insulin therapy. The rising prevalence of Type 1 diabetes is driven by genetic factors, environmental triggers, and increasing autoimmune disorders. Short-acting insulin helps manage type 1 diabetes by providing rapid blood sugar control and mimicking natural insulin response. For instance, in 2023, according to Diabetes Australia, an Australia-based organization that works to raise awareness about diabetes, in 2022, approximately 134,000 Australians were living with Type 1 diabetes. This figure increased to 135,423 in 2023. Therefore, the increasing prevalence of type 1 diabetes is driving the growth of the short-acting insulin market.
What are the key segments within the short-acting insulin market?
The short-acting insulin market covered in this report is segmented –
1) By Formulation: Regular Insulin, Rapid-Acting Insulin
2) By Dosage Form: Vials, Pre-filled Pens, Cartridges
3) By Route Of Administration: Subcutaneous, Intravenous
4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes
5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies
Subsegments:
1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin
2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report
Which key players are shaping the short-acting insulin market?
Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., Adocia S.A.S.
How will emerging trends drive the short-acting insulin market throughout the forecast period?
Major companies operating in the short-acting insulin market are focusing on innovative products such as insulin pods to provide continuous insulin infusion and adherence for individuals with diabetes. An insulin pod refers to a tubeless, wearable insulin delivery system that provides continuous insulin infusion for diabetes management. For instance, in April 2023, Insulet Corporation, a US-based medical device company, announced U.S. Food and Drug Administration (FDA) clearance for Omnipod GO, a groundbreaking basal-only insulin pod designed for adults with type 2 diabetes. This tubeless, wearable device offers continuous insulin delivery without the need for a separate controller. Omnipod GO simplifies diabetes management by eliminating daily injections and providing pre-programmed insulin rates. With its user-friendly design and pharmacy accessibility, it enhances convenience for both patients and healthcare providers. This launch reinforces Insulet’s commitment to improving diabetes care through innovative technology.
How do regional factors impact the short-acting insulin market, and which region is the largest contributor?
North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Short-Acting Insulin Market Report 2025 Offer?
The short-acting insulin market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Short-acting insulin is a type of insulin that is used to control blood sugar levels during or after meals. It begins to work within 30 minutes to 1 hour, peaks at around 2-3 hours, and has a duration of action of 4-6 hours. Short-acting insulin plays a vital role in regulating blood glucose by facilitating the uptake of glucose into cells, which the body then uses for energy, particularly after the consumption of food.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21287
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
